Evidence map›Paper›PMID 32498542›Full record

ArticleAIDS research and human retroviruses2020

Comparison of HIV Incidence in the Zimbabwe Population-Based HIV Impact Assessment Survey (2015-2016) with Modeled Estimates: Progress Toward Epidemic Control.

Elizabeth Gonese, Godfrey Musuka, Leala Ruangtragool, Avi Hakim, Bharat Parekh, Trudy Dobbs, Yen T Duong, Hetal Patel, Mutsa Mhangara, Owen Mugurungi and 7 more

Open access · greenAbstract readComparative Study
In one paragraph

Article in AIDS research and human retroviruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 3 countries.

Elizabeth GoneseDivision of Global AIDS and TB, U.S. Centers for Disease Control and Prevention, Harare, Zimbabwe.
Godfrey MusukaICAP at Columbia University, Harare, Zimbabwe.
Leala RuangtragoolCenters for Disease Control and Prevention, Harare, Zimbabwe.
Avi HakimDivision of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Bharat ParekhInternational Lab Branch, Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Trudy DobbsInternational Lab Branch, Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Yen T DuongICAP at Columbia University, New York, New York, USA.
Hetal PatelInternational Lab Branch, Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Mutsa MhangaraAIDS and TB Unit, Ministry of Health and Child Care, Harare, Zimbabwe.
Owen MugurungiAIDS and TB Unit, Ministry of Health and Child Care, Harare, Zimbabwe.
Munyaradzi MapingureICAP at Columbia University, Harare, Zimbabwe.
Suzue SaitoICAP at Columbia University, New York, New York, USA.
Amy Herman-RoloffDivision of Global AIDS and TB, U.S. Centers for Disease Control and Prevention, Harare, Zimbabwe.
Lovemore GwanzuraBiomedical Research and Training Institute, Harare, Zimbabwe.
Beth Tippett-BarrDivision of Global AIDS and TB, U.S. Centers for Disease Control and Prevention, Harare, Zimbabwe.
Peter H KilmarxDivision of Global AIDS and TB, U.S. Centers for Disease Control and Prevention, Harare, Zimbabwe.
Jessica JustmanICAP at Columbia University, New York, New York, USA.
Centers for Disease Control and Prevention · UGColumbia University · USMinistry of Health and Child Welfare · ZWBiomedical Research and Training Institute · ZWCenter for Global Health · USICAP Global Health

Funding

CGH CDC HHS U2G GH000994Intramural CDC HHS CC999999
6 · The paper itself

Abstract

Between October 2015 and August 2016, Zimbabwe conducted the Zimbabwe Population-Based HIV Impact Assessment (ZIMPHIA) cross-sectional survey to determine progress toward epidemic control. Of 25,131 eligible adults aged 15-64 years, 20,577 (81.8%) consented to face-to-face questionnaire and biomarker testing in this nationally representative household survey. Home-based rapid HIV testing was performed using Determine, First Response, and STAT-PAK as the tiebreaker. HIV-positive tests were confirmed in a laboratory using Geenius HIV-1/2; viral load (VL) was measured using Roche TaqMan and BioMerieux NucliSENS. Recency of infection was tested using Sedia HIV-1 Limiting Antigen (LAg)-Avidity. Presence of antiretroviral (ARV) drugs was detected using high performance liquid chromatography/mass spectrometry (HPLC/MS). The recent infection testing algorithm included LAg-avidity enzyme immunoassay [normalized optical density (ODn ≤1.5), VL ≥1,000 copies/mL, and absence of ARV drugs]. Weighted annual HIV incidence was compared with United Nations Joint Programme on HIV/AIDS (UNAIDS) Spectrum models estimates. Overall, 26 of 2,901 HIV-seropositive individuals had a recent infection (men, 8; women, 18). Overall weighted annual incidence among persons aged 15-64 years was 0.42% [95% confidence interval (CI): 0.25-0.59] and was 0.44% (95% CI: 0.25-0.62) for those aged 15-49 years, similar to 2016 Spectrum model estimate (0.54%, 95% CI: 0.49-0.66) for this age group. Among persons aged 15-49 years, HIV prevalence was 13.35% (95% CI: 12.71-14.02), estimated HIV-positive individuals were 968,951 (95% CI: 911,473-1,026,430), of these, 41,911 (95% CI: 37,412-44,787) were annual-new infections, and this was similar to 2016 Spectrum estimates. The observed HIV incidence in ZIMPHIA 2015-2016 validated the 2016 Spectrum estimates and Zimbabwe's progress toward epidemic control.

Indexed as

Models, StatisticalAdolescentAdultAnti-Retroviral AgentsCross-Sectional StudiesEpidemicsHIV InfectionsHumansMiddle AgedPrevalenceSerologic TestsSurveys and QuestionnairesViral LoadYoung AdultZimbabweAnti-Retroviral AgentscomparisonincidenceSpectrum

Identifiers

PMID32498542
PMCPMC7986968
OpenAlexW3033918891

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.